In 2024, it's estimated that 2,001,140 new cancer cases will be diagnosed in the United States, excluding basal and squamous cell skin cancers (1). Of those, approximately 14,910 are expected to be children and adolescents aged 0 to 19, and tragically, an estimated 1,590 will die from the disease (2). This highlights the harsh reality that cancer can affect anyone, regardless of age, income, or location. While overall cancer mortality rates have been decreasing, incidence rates for some cancers continue to rise, and significant disparities in cancer outcomes persist among different racial and ethnic groups. Unfortunately, only a small percentage of the billions of dollars allocated for cancer research is directed towards pediatric cancer. This lack of funding hinders the development of new, more effective treatments, leaving many children reliant on therapies developed decades ago (2).
(1) American Cancer Society: Cancer Facts & Figures 2024.
(2) National Cancer Institute (NCI).
Unfortunately, it can affect any of us, regardless of income, where we live, or even our age. Of the billions of dollars available for cancer research, only 4% is directed toward pediatric cancer research. Most current pediatric cancer treatments were approved 32 years ago(4).
We can change that by raising funds that support pediatric cancer research and treatment centers. We can also try to make the time during treatment just a bit more manageable.
The mission of the Mini Sticks Charitable Organization (a 501(c)3) is to support kids and their families affected by cancer with a simple vision: provide an escape from cancer.
You can help when you ‘Score to Support.’
The Mini Sticks CO 204-25 Season Impact Summary
In 2024-25 we leveraged our platform and shifted our focus to increasing awareness of pediatric cancer. Check out our latest impact summary to see what we accomplished!
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.